Amgen ’s Repatha shows positive outcome in Phase III trial for cardiovascular disease

US-based biopharmaceutical firm Amgen has reported positive outcome for Repatha (evolocumab) in the Phase III FOURIER trial to treat patients suffering from cardiovascular disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news